Attorney Docket No. RCK-62

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE 0/574122

In re application of: Axel Bouchon, et al.

Serial No.: [to be assigned] - National Stage Filing of PCT/EP2004/010606

Title: Tetrahydro-Naphthalene and Urea Derivatives

MAIL STOP PCT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN THREE MONTHS OF DATE OF NATIONAL STAGE ENTRY 37 C.F.R. 1.97(b)(2)

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying form(s) PTO/SB/08A-B [substitute for form 1449/PTO]. A copy of the International Search Report is also enclosed for your reference.

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed concurrently with the request under 35 U.S.C. § 371(f) to begin national examination procedures.

FEE PAYMENT

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted.

William F. Gray Reg. No.: 31,018

Attorney for Applicant(s)

Bayer Pharmaceuticals Corporation 400 Morgan Lane, West Haven, CT 06516 Telephone: (203) 812-6450

Facsimile: (203) 812-6459

IAP5 Rec'd PCT/PTO 3 1 MAR 2006

PTO/SB/08A (07-05) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute	for form 1449/PTO			Complete if Known				
				Application Number	[to be a spigged] 57412			
INEC	RMATIO	N DISC	OCHDE	Filing Date	101-21-1-			
				First Named Inventor	Axel Bouchon			
STA	TEMENT	BY APP	PLICANT	Art Unit				
	(Use as many s	heets as neces	ssary)	Examiner Name				
heet	1	of	2	Attorney Docket Number	RCK-62			

			U. S. PATENT D			
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	-	US-	 		3	
		US-				
		US-				
		US-				
		US-				
		US-			,	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-			-	
		US-	1	······································		
		US-				
		US-				
		US-	<u> </u>			
		US-				
	†	US-	 			

		FOREIG	N PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY			T ⁶
	F1	WO 2004/052845 A1	06/24/2004	Bayer HealthCare AG		
	F2	WO 03/022809 A2	03/20/2003	SmithKline Beecham P	L.C.	
	F3	WO 03/068749 A1	08/21/2003	Glaxo Group Limited		
	F4	WO 03/014064 A1	02/20/2003	Bayer Aktiengesellscha	ft	
	F5	WO 02/08221 A2	01/31/2002	Neurogen Corporation		

Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

IAP5 Rec'd PCT/PTO 3 1 MAR 2006

PTO/SB/08B (07-05) Approved for use through 07/31/2006. OMB 0651-0031

Complete if Known

[to be assigned]

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Number

Substitute for form 1449/PTO

INFO	RMAT	I MOIT	DIS	CLOSURE	Filing Date				
(Use as many sheets as necessary)					First Named Inventor Axel Bouchon Art Unit				
								Examiner Name	
					Sheet	2		of	2
				NON DAM		WIMPNITO			
Examiner Initials*	Cite No. ¹			me of the author (i		of the article (when appropriate), title of alog, etc.), date, page(s), volume-issue	T ²		
	R1	Patent Abstract of Japan, Vol. 2003, No. 11, 5 November 2003 (2003-11-05) & JP 2003 192673 A (Bayer AG)							
			-		.,				
			· · · · · · · · · · · · · · · · · · ·						

	4		
	·		
	 ·		
Examiner		Date	1
		Date	
Signature		Considered	1
O.g. latare		Constacted	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO This collection of Information is required by 37 CPR 1.96. The information is required to obtain or retain a benefit by the public which is to line tails by the Ost To to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.